KR20240046744A - 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법 - Google Patents
면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20240046744A KR20240046744A KR1020247007625A KR20247007625A KR20240046744A KR 20240046744 A KR20240046744 A KR 20240046744A KR 1020247007625 A KR1020247007625 A KR 1020247007625A KR 20247007625 A KR20247007625 A KR 20247007625A KR 20240046744 A KR20240046744 A KR 20240046744A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- composition
- compound
- subject
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233163P | 2021-08-13 | 2021-08-13 | |
| US63/233,163 | 2021-08-13 | ||
| PCT/US2022/074903 WO2023019242A1 (en) | 2021-08-13 | 2022-08-12 | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240046744A true KR20240046744A (ko) | 2024-04-09 |
Family
ID=83192025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007625A Pending KR20240046744A (ko) | 2021-08-13 | 2022-08-12 | 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240351977A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4384495A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024532810A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240046744A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118076582A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3228238A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023019242A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12697320B2 (en) | 2021-01-29 | 2026-08-04 | Tim Therapeutics, Inc. | Tartaric acid analogs and uses thereof |
| CN117940407A (zh) | 2021-08-13 | 2024-04-26 | Lapix生物治疗股份有限公司 | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 |
| US20260144239A1 (en) | 2022-10-25 | 2026-05-28 | Lapix Therapeutics, Inc. | Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models |
| WO2024118602A1 (en) | 2022-11-29 | 2024-06-06 | Lapix Therapeutics, Inc. | Compositions and methods for reducing immune intolerance and treating autoimmune disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859284B2 (en) * | 2009-10-22 | 2014-10-14 | The United States Of America, As Represented By The Secretary Of The Navy | Delivery of nanoparticles to neurons |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| JP6783652B2 (ja) * | 2013-09-24 | 2020-11-11 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 抗原特異的免疫原性を低減するための組成物及び方法 |
| ES2952038T3 (es) * | 2016-04-05 | 2023-10-26 | Univ New York State Res Found | Composiciones que contienen fosfoserina para la inducción de la tolerancia inmune |
| US20240173389A1 (en) * | 2021-03-11 | 2024-05-30 | Lapix Therapeutics, Inc. | Compositions and Methods For Reducing Immune Intolerance |
-
2022
- 2022-08-12 EP EP22764981.1A patent/EP4384495A1/en active Pending
- 2022-08-12 KR KR1020247007625A patent/KR20240046744A/ko active Pending
- 2022-08-12 CN CN202280068028.1A patent/CN118076582A/zh active Pending
- 2022-08-12 JP JP2024508786A patent/JP2024532810A/ja active Pending
- 2022-08-12 CA CA3228238A patent/CA3228238A1/en active Pending
- 2022-08-12 US US18/579,943 patent/US20240351977A1/en active Pending
- 2022-08-12 WO PCT/US2022/074903 patent/WO2023019242A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024532810A (ja) | 2024-09-10 |
| WO2023019242A9 (en) | 2023-04-20 |
| CA3228238A1 (en) | 2023-02-16 |
| WO2023019242A1 (en) | 2023-02-16 |
| EP4384495A1 (en) | 2024-06-19 |
| US20240351977A1 (en) | 2024-10-24 |
| CN118076582A (zh) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240351977A1 (en) | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | |
| US20240173389A1 (en) | Compositions and Methods For Reducing Immune Intolerance | |
| JP7169968B2 (ja) | ワクチンアジュバント製剤 | |
| KR20220129001A (ko) | 치료제의 표적 전달을 위한 조작된 혈소판 | |
| CN111989123B (zh) | 用于药物递送的组合物和方法 | |
| US12016836B2 (en) | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | |
| US20220280557A1 (en) | Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders | |
| BR112020015071A2 (pt) | Conjugados de anticorpos liberáveis | |
| US20220226499A1 (en) | Metabolite Delivery for Modulating Metabolic Pathways of Cells | |
| US20240226104A1 (en) | Pi3k inhibitors, nanoformulations, and uses thereof | |
| JP2023502182A (ja) | がんの処置において有用なidoアンタゴニストプロドラッグを含有する製剤化および/または共製剤化されたリポソーム組成物およびその方法 | |
| US20160024178A1 (en) | Compounds for treating neurodegenerative proteinopathies | |
| CN117820149B (zh) | 可电离脂质化合物 | |
| ES2993108T3 (en) | A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases | |
| WO2024118602A1 (en) | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | |
| JP2025514198A (ja) | 二重機能免疫調節化合物、製剤、及びその使用 | |
| HK40107073A (en) | Pi3k inhibitors, nanoformulations, and uses thereof | |
| WO2025194120A1 (en) | Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |